Persistent bone marrow failure with dysplastic features following pentostatin therapy for hairy cell leukaemia

Clinical and Laboratory Haematology

Volumn 20, Issue 3, 1998, Pages 195-197

  Psiachou Leonard, E ^a   Bain, B J ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Hairy cell leukaemia; Myelodysplastic syndromes; Pentostatin; Refractory anaemia with ring sideroblasts

Indexed keywords

ALKYLATING AGENT; NUCLEOSIDE ANALOG; PENTOSTATIN;

AGED; ANEMIA; ARTICLE; BONE MARROW DEPRESSION; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; HAIRY CELL LEUKEMIA; HUMAN; MALE; MYELODYSPLASIA; PRIORITY JOURNAL;

ADENOSINE DEAMINASE; AGED; ANEMIA, REFRACTORY; ANTIBIOTICS, ANTINEOPLASTIC; BLOOD TRANSFUSION; BONE MARROW; COMBINED MODALITY THERAPY; ENZYME INHIBITORS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, HAIRY CELL; MALE; NEUTROPENIA; PENTOSTATIN; REMISSION INDUCTION;

EID: 0031838363     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2257.1998.00118.x     Document Type: Article

References (8)

1. Catovsky D., Matutes E., Talavera J.G et al. (1994) Long term results with 2-deoxycoformycin in hairy cell leukaemia, Leukemia and Lymphoma 14 (Suppl. 1), 109-113.
2. Cheson B.D. (1995) Infectious and immunosuppressive complications of purine nucleoside analog therapy. Journal of Clinical Oncology 19, 2431-2448.
3. Frewin R.J., Provan D. & Smith A.G. (1997) Myelodysplasia occuring after fludarabine treatment for chronic lymphocytic leukaemia. Clinical and Laboratory Haematology 19, 151-152.
4. Kroft S.H., Tallman M.S., Shaw J.M., Thangavelu M. & Peterson L.C. (1997) Myelodysplasia following treatment of chronic lymphocytic leukaemia (CLL) with 2-chlorodeoxyadenosine (2-CdA). Leukemia 11, 170.
5. Laurencet F.M., Zulian G.B., Cabrol C. & Betticher D.C. (1997) Myelodysplastic syndrome with biclonal monosomy 7 and trisomy 8 after treatment with cladribine (2-chloro-2-deoxyadenosine) and involved field radiotherapy. Cancer Genetics and Cytogenetics 99, 85-89.
6. Orchard J.A., Bolam S. & Oscier D.G. (1998) Association of myelodysplastic changes with purine analogues. British Journal of Haematology 100, 677-679.
7. Orchard J.A., Bolam S. & Oscier D.G. (1996) Incidence of dysplastic changes in patients with lymphoproliferative disorders after treatment with purine analogues. Blood 88 (Suppl. 1), 209b.
8. Tallman M.S. & Hakimian D. (1995) Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 86, 2463-2474.